Based on our above findings of p-FAK upregulation under ROS1 inhibitor resistance, we next tested whether inhibiting FAK activity could restore the negative impact of ROS1 inhibitors on cancer cell proliferation in vitro using CTG assays in the five CDH1-deficient cell lines. Here, ROS1 is linked to cancer.